Medicine and Dentistry
Non Small Cell Lung Cancer
96%
Lung Cancer
45%
Neoplasm
43%
Circulating Tumor Cell
40%
Immune Checkpoint Inhibitor
22%
Overall Survival
20%
Epidermal Growth Factor Receptor
17%
Malignant Neoplasm
17%
Small Cell Lung Cancer
16%
Immunotherapy
15%
Diagnosis
15%
Quality of Life
14%
Disease
14%
Progression Free Survival
13%
Nivolumab
13%
Radiation Therapy
12%
Durvalumab
10%
Epithelial Cell Adhesion Molecule
9%
Oncology
9%
Leukapheresis
9%
Writing
9%
Asthma
9%
Patient Referral
8%
Programmed Death 1 Ligand 1
8%
Targeted Therapy
8%
Exon
8%
Hazard Ratio
8%
Adverse Event
8%
Circulating Tumor DNA
8%
Tyrosine-Kinase Inhibitor
7%
Randomized Controlled Trial
7%
Biological Marker
6%
Non-Small Cell Lung Cancer
6%
ALK Inhibitor
6%
COVID-19
6%
Resistance Mutation
6%
Cohort Analysis
6%
Disease Exacerbation
6%
Platelet
6%
Primary Health Care
6%
Cancer Stem Cell
6%
Pooled Analysis
6%
Secondary Care
6%
Chemoimmunotherapy
6%
Biopsy
6%
Crizotinib
5%
Chemoradiotherapy
5%
Primary Tumor
5%
Pembrolizumab
5%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
100%
Neoplasm
51%
Lung Cancer
47%
Epidermal Growth Factor Receptor
30%
Immune Checkpoint Inhibitor
28%
Overall Survival
27%
Chemotherapy
26%
Biological Marker
20%
Disease
17%
Small Cell Lung Cancer
16%
Nivolumab
16%
Progression Free Survival
15%
Chemoradiation Therapy
15%
Asthma
15%
Durvalumab
14%
Protein Tyrosine Kinase Inhibitor
13%
Malignant Neoplasm
12%
Adverse Event
12%
Immunotherapy
10%
Circulating Tumor DNA
10%
Randomized Controlled Trial
9%
Disease Exacerbation
9%
Erlotinib
9%
Placebo
7%
Anaplastic Lymphoma Kinase Inhibitor
7%
Crizotinib
7%
Methacholine
7%
Afatinib
6%
Respiratory Tract Allergy
6%
Carboplatin
6%
Osimertinib
6%
Docetaxel
6%
Programmed Death 1 Ligand 1
6%
Anaplastic Lymphoma Kinase
6%
Epithelial Cell Adhesion Molecule
6%
Keyphrases
Non-small Cell Lung Cancer (NSCLC)
26%
Lung Cancer
22%
Immune Checkpoint Inhibitors
20%
Circulating Tumor Cells
12%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
11%
Netherlands
10%
Overall Survival
9%
Chemotherapy
9%
Nivolumab
9%
Asthmatic
9%
Non-small Cell Lung Cancer Patients
9%
Hazard Ratio
8%
Tumor Response
8%
Quality of Life
8%
Asthma
7%
Chemoradiotherapy
6%
Dutch
6%
Groningen
6%
Older Patients
6%
Treatment Goals
6%
Epidermal Growth Factor Receptor
6%
Prioritization Tool
6%
Advanced Lung Adenocarcinoma
6%
Genomic Scars
6%
MRNA-1273
6%
Mutational Profile
6%
Molecular Tumor Board
6%
Immune Checkpoint Inhibitor Treatment
6%
Diagnostic Leukapheresis
5%
University Medical Centre
5%
Progression-free Survival
5%
